Valeant Declines on Report That Drugmaker Faces Lender Pressure

  • Stock falls as much as 11% after report on debt talks
  • Lenders said to be pushing for new terms, Reuters reports

Valeant Pharmaceuticals International Inc. shares plunged as much as 11 percent on Thursday, dropping to prices last seen in January 2011 after a report that lenders are pressing for new terms.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.